Invitrogen Up Almost 11 Percent on BioReliance Sale, EPS Performance

Feb 14, 2007

NEW YORK (GenomeWeb News) — Shares in Invitrogen were up nearly 10.5 percent at $66.73 in mid-afternoon trading after the company reported yesterday it would sell its flagging BioReliance business, and that its fourth-quarter earnings per share beat Wall Street expectations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Who Are You?

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

'Problematic'

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Republicans Take on Peer Review

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

This Week in Science

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Main menu